GH Research
GHRS
21.06
-0.46
-2.14%
GH Research
US · GHRS
#2969 by market cap
Listed 2021
21.06
-0.46
-2.14%
Live - 5344 symbols - heartbeat 330s ago
· 2026-10-08 07:39
Pre-market
21.04
-0.09%
After-hours
21.00
-0.28%
- Market cap
- 1.45B
- P/E (TTM)i
- -21.27
- P/Bi
- 4.02
- EPSi
- -0.79
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on GHRS?
Anonymous reader poll. Unscientific, not investment advice.
About GH Research
GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Sch?nharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
- Founded
- 2021
- CEO
- Dr. Velichka Valcheva, M.D.,M.Sc.
- Employees
- 73
- Headquarters
- Dublin, Dublin, Ireland
- Fiscal year end
- 12-31
- Website
- ghres.com
Company profile
- Exchange
- US
- Symbol
- GHRS
- Market-cap rank
- #2969
- Listing date
- 2021-06-25
- Market cap
- 1.45B
- Float cap
- 681.74M
- Shares out
- 68.64M
- Float shares
- 32.37M
Sectors & themes
Quote time 2026-10-08 07:39:09 · For reference only, not investment advice and not tailored to your situation.